CureVac B.V. (CVAC)

[@LaughinPaulRyan]

... UH DUH $CVAC IS A BUY ...

On September 29, 2020, CureVac N.V. (the “Company”) issued a press release announcing that the Company has initiated a Phase 2a clinical trial of its COVID-19 vaccine candidate, CvnCoV. The dose-confirmation study, CV-NCOV-002, is being conducted in Peru and Panama and is expected to enroll a total of 690 healthy participants in two groups: older adults ages 61 and above, and younger participants 18 to 60 years old. The press release is attached hereto as Exhibit 99.1.

The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.